Akshay Madan1, Sandeep K Ganji1,2, Zhongxu An1,2, Kevin S Choe3,4, Marco C Pinho1,2, Robert M Bachoo3,5,6,7, Elizabeth M Maher3,5,6,7, Changho Choi1,2,3. 1. Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 2. Department of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 3. Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 4. Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 5. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 6. Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 7. Annette Strauss Center for Neuro-Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Abstract
PURPOSE: To evaluate the T2 relaxation time of lactate (Lac) in brain tumors and the correlation of the T2 and concentration with tumor grades. METHODS: Eight pairs of the subecho time sets of point-resolved spectroscopy were selected between 58 and 268 ms, with numerical and phantom analyses, for Lac T2 measurement. In vivo spectra were acquired from 24 subjects with gliomas (13 low grade and 11 high grade) and analyzed with LCModel using numerically-calculated basis spectra. The metabolite T2 relaxation time was obtained from monoexponential fitting of the multi-echo time (TE) signal estimates versus TE. The metabolite concentration was estimated from the zero-TE extrapolation of the T2 fits. RESULTS: The Lac T2 was estimated to be approximately 240 ms, without a significant difference between low and high grade tumors. The Lac concentration was estimated to be 4.1 ± 3.4 and 7.0 ± 4.7 mM for low and high grades respectively, but the difference was not significant. CONCLUSION: The Lac T2 was similar among gliomas regardless of their tumor grades. This suggests that the T2 value from this study may be applicable to obtain the T2 relaxation-free estimates of Lac in a subset of brain tumors.
PURPOSE: To evaluate the T2 relaxation time of lactate (Lac) in brain tumors and the correlation of the T2 and concentration with tumor grades. METHODS: Eight pairs of the subecho time sets of point-resolved spectroscopy were selected between 58 and 268 ms, with numerical and phantom analyses, for Lac T2 measurement. In vivo spectra were acquired from 24 subjects with gliomas (13 low grade and 11 high grade) and analyzed with LCModel using numerically-calculated basis spectra. The metabolite T2 relaxation time was obtained from monoexponential fitting of the multi-echo time (TE) signal estimates versus TE. The metabolite concentration was estimated from the zero-TE extrapolation of the T2 fits. RESULTS: The Lac T2 was estimated to be approximately 240 ms, without a significant difference between low and high grade tumors. The Lac concentration was estimated to be 4.1 ± 3.4 and 7.0 ± 4.7 mM for low and high grades respectively, but the difference was not significant. CONCLUSION: The Lac T2 was similar among gliomas regardless of their tumor grades. This suggests that the T2 value from this study may be applicable to obtain the T2 relaxation-free estimates of Lac in a subset of brain tumors.
Authors: F A Howe; S J Barton; S A Cudlip; M Stubbs; D E Saunders; M Murphy; P Wilkins; K S Opstad; V L Doyle; M A McLean; B A Bell; J R Griffiths Journal: Magn Reson Med Date: 2003-02 Impact factor: 4.668
Authors: D Sappey-Marinier; G Calabrese; H P Hetherington; S N Fisher; R Deicken; C Van Dyke; G Fein; M W Weiner Journal: Magn Reson Med Date: 1992-08 Impact factor: 4.668
Authors: Changho Choi; Sandeep K Ganji; Ralph J DeBerardinis; Kimmo J Hatanpaa; Dinesh Rakheja; Zoltan Kovacs; Xiao-Li Yang; Tomoyuki Mashimo; Jack M Raisanen; Isaac Marin-Valencia; Juan M Pascual; Christopher J Madden; Bruce E Mickey; Craig R Malloy; Robert M Bachoo; Elizabeth A Maher Journal: Nat Med Date: 2012-01-26 Impact factor: 53.440
Authors: A Berrington; K C Schreck; B J Barron; L Blair; D D M Lin; A L Hartman; E Kossoff; L Easter; C T Whitlow; Y Jung; F-C Hsu; M C Cervenka; J O Blakeley; P B Barker; R E Strowd Journal: AJNR Am J Neuroradiol Date: 2019-10-24 Impact factor: 3.825
Authors: Vivek Tiwari; Zhongxu An; Sandeep K Ganji; Jeannie Baxter; Toral R Patel; Edward Pan; Bruce E Mickey; Elizabeth A Maher; Marco C Pinho; Changho Choi Journal: NMR Biomed Date: 2017-05-26 Impact factor: 4.044
Authors: Zhongxu An; Vivek Tiwari; Jeannie Baxter; Michael Levy; Kimmo J Hatanpaa; Edward Pan; Elizabeth A Maher; Toral R Patel; Bruce E Mickey; Changho Choi Journal: Magn Reson Med Date: 2018-09-14 Impact factor: 4.668
Authors: Zhongxu An; Sandeep K Ganji; Vivek Tiwari; Marco C Pinho; Toral Patel; Samuel Barnett; Edward Pan; Bruce E Mickey; Elizabeth A Maher; Changho Choi Journal: Magn Reson Med Date: 2016-07-25 Impact factor: 4.668
Authors: Sandeep K Ganji; Zhongxu An; Vivek Tiwari; Sarah McNeil; Marco C Pinho; Edward Pan; Bruce E Mickey; Elizabeth A Maher; Changho Choi Journal: Magn Reson Med Date: 2016-03-16 Impact factor: 4.668
Authors: Vivek Tiwari; Tomoyuki Mashimo; Zhongxu An; Vamsidhara Vemireddy; Sara Piccirillo; Pegah Askari; Keith M Hulsey; Shanrong Zhang; Robin A de Graaf; Toral R Patel; Edward Pan; Bruce E Mickey; Elizabeth A Maher; Robert M Bachoo; Changho Choi Journal: Magn Reson Med Date: 2020-01-30 Impact factor: 4.668
Authors: In-Young Choi; Ovidiu C Andronesi; Peter Barker; Wolfgang Bogner; Richard A E Edden; Lana G Kaiser; Phil Lee; Małgorzata Marjańska; Melissa Terpstra; Robin A de Graaf Journal: NMR Biomed Date: 2020-09-18 Impact factor: 4.044
Authors: Yury Koush; Robin A de Graaf; Ron Kupers; Laurence Dricot; Maurice Ptito; Kevin L Behar; Douglas L Rothman; Fahmeed Hyder Journal: J Cereb Blood Flow Metab Date: 2021-01-20 Impact factor: 6.200